SINGAPORE - MSD's new investment here will put Singapore at the heart of its revamped global supply chain from where the US drugmaker will produce and distribute its latest innovative medicine and vaccines.
The new manufacturing facilities and investments in digitalisation and automation will enhance distribution capabilities, lowering the risk of supply disruptions, said Mr David Peacock, the Asia-Pacific president of MSD - a firm known as Merck & Co in the United States and Canada.
Already a subscriber? Log in
Read the full story and more at $9.90/month
Get exclusive reports and insights with more than 500 subscriber-only articles every month
ST One Digital
$9.90/month
No contract
ST app access on 1 mobile device
Unlock these benefits
All subscriber-only content on ST app and straitstimes.com
Easy access any time via ST app on 1 mobile device
E-paper with 2-week archive so you won't miss out on content that matters to you
